Ku-Lung Hsu

Technologies

• Irreversible DGKα inhibitors for enhanced T‑cell activation in cancer immunotherapy
• Sulfonyl-purine probes for covalent targeting of lysine and tyrosine in drug discovery
• Sulfonyl-triazole activators for cell-selective glycolysis enhancement in cancer and Parkinson’s disease
• PhAzE chemistry for selective covalent modification of protein tyrosine and lysine residues
• New approach to fight hormone dependent cancers using covalent inhibition of AKR1C3